Acquisition - December 12, 2015
Global report: Pfizer buys Allergan
In the end of November, Pfizer acquired Allergan for more than $150 billion, a deal which will create the world’s biggest drug maker. The deal, the largest ever in the healthcare sector, involves Pfizer paying with 11.3 of its shares for each Allergan share. There will also be a small cash component, accounting for less […]
Acquisition - November 23, 2015
Pfizer buys Allergan
Pfizer has acquired Allergan for more than $150 billion, a deal that will create the world’s biggest drug maker. The deal, the largest ever in the healthcare sector and involves Pfizer paying with 11.3 of its shares for each Allergan share. There will also be a small cash component, accounting for less than 10 percent of the […]
Global report - September 18, 2015
A paradigm shift in diabetes medicine
A new diabetes medicine has shown significant reduction in both cardiovascular risk and cardiovascular death in a dedicated outcome trial. The results was presented yesterday at the European Association for the Study of Diabetes (EASD) in Stockholm. The study, supported by Boehringer Ingelheim Pharmaceuticals and Eli Lilly and Company, shows that Jardiance® (empagliflozin) significantly reduced the […]
Global report - July 15, 2015
World Not Ready for ‘Superbugs’
Only 34 countries have national plans to fight antibiotic resistance, which means very few are prepared to tackle an outbreak of a “superbug” infection, according to the World Health Organization (WHO). The 34 nations that indicated they were addressing the problem represent a quarter of the 133 countries that responded to a recent WHO survey. […]
Global report - May 15, 2015
Data Lacking on Ebola Vaccines
With Ebola nearly eliminated in West Africa, vaccine trials probably will fail to provide enough useful data on how well they protect people against the virus, the World Health Organization (WHO) said. Liberia was declared free from Ebola by the government and the WHO recently after 42 days without a new case of the virus, […]
Global report - October 6, 2014
EMA adopts open trial data policy
The European Medicines Agency (EMA) has decided to publish the clinical reports that underpin the decision-making on medicines. The new landmark policy will take effect on 1 January 2015. It will apply to clinical reports contained in all applications for centralised marketing authorisations submitted after that date. The reports will be released as soon as […]
